Why ChatGPT and Co-pilot are not safe for pharma and what to use instead

Generative AI tools like ChatGPT and Microsoft Copilot are transforming industries but in pharma and medical, they could be putting your compliance at serious risk.

Here's what you need to know.

What is generative AI and why does it matter for pharma?

Generative AI, including large language models (LLMs) like ChatGPT, is designed to generate answers. That sounds useful and for creative writing, brainstorming or content ideation, it is. But in pharmaceutical, clinical and medical environments, generating an answer is not the same as finding the correct answer.

The core problem: Generative AI is non-deterministic. That means you cannot predict or control what answer it will produce. Ask it the same compliance-critical question twice and you may get two different responses neither grounded in verified clinical evidence.

The biggest risk: AI hallucination in pharma

One of the most well-documented dangers of large language models in regulated industries is AI hallucination where the model confidently generates false or unverified information. This is especially dangerous when:

• Medical professionals are relying on AI for drug information

• Regulatory teams need evidence-backed responses

• Clinical study data must be cited accurately

• Compliance-first workflows require traceable, auditable answers

ChatGPT and similar tools are not designed to verify information against your approved documents. They are designed to respond to the intent of your question including leading questions by generating a plausible-sounding answer. In pharma, a plausible answer is not good enough.

What Is a retrieval-based AI? and why Is it better for pharma?

Unlike generative AI, a retrieval-based AI or retrieval-augmented generation (RAG) system doesn't generate answers from scratch. Instead, it searches within a defined, approved knowledge base your documents, your clinical studies, your verified content and returns answers with direct citations.

This is the fundamental difference between:

Introducing compliance-first AI for pharma: RoseRx

RoseRx is purpose-built to solve the compliance gap that generative AI cannot address.

Here's how it works:

1. Your team uploads approved documents, clinical studies, product information, regulatory content

2. RoseRx reads and indexes the content, generating questions and answers with citations before the knowledge base goes live

3. Every response is grounded in your approved documents, with highlighted passage-level citations

4. If a question falls outside the knowledge base, the system falls back to your documents to generate an answer, it will never pull information from the web or fabricate a response

5. New questions can be reviewed and added to your knowledge base, keeping your AI continuously compliant and up to date

Why deterministic AI matters in regulated industries

What does deterministic AI mean? A deterministic AI system produces consistent, verifiable and traceable outputs based on a controlled set of inputs, in this case, your approved content.

For pharma, medical and clinical teams, deterministic AI is not a nice-to-have. It is a regulatory requirement.

You need to know:

• Where every answer came from

• Which document and passage it references

• What happens when a document is updated or removed

• That no answer is being fabricated or extrapolated

RoseRx tracks all of this. Update a document? The system tracks it. Remove a clinical study? Citations are updated, you are never left with unverified or uncited information in your knowledge base.

The bottom line: Pharma needs more than a chatbot

The AI tools dominating the consumer space were built for creative, conversational, and generative tasks. They were not built for the compliance demands of the pharmaceutical and medical industries.

A pharma-grade AI platform must be:

• Grounded in real-world evidence

• Backed by citations at every response

• Restricted to your approved knowledge base

• Deterministic and auditable

• Built for compliance, not just conversation

If your organization is evaluating AI for medical information, clinical content or regulatory workflows, the question is not whether to use AI, it's which kind of AI is safe to use.